Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/25/2025

Treatment of Trichotillomania

First-Line Treatment: Behavioral Therapy

  • Habit reversal training should be initiated as the primary treatment modality for all patients with trichotillomania, according to the Journal of Child Psychology and Psychiatry and Allied Disciplines 1
  • Awareness training, a component of habit reversal training, helps patients learn to identify triggers, situations, and early warning signs that precede hair-pulling episodes, as recommended by the Journal of Child Psychology and Psychiatry and Allied Disciplines 1
  • Competing response training, another component of habit reversal training, involves patients practicing alternative behaviors when the urge to pull hair emerges, as suggested by the Journal of Child Psychology and Psychiatry and Allied Disciplines 1
  • Developing a relapse prevention plan that identifies triggers, warning signs, and action steps is crucial for maintaining treatment gains, according to the Journal of Child Psychology and Psychiatry and Allied Disciplines 1

Treatment Structure

  • 10-20 sessions of individual or group cognitive-behavioral therapy are recommended, as stated in Nature Reviews Disease Primers 2
  • In-person or internet-based delivery of cognitive-behavioral therapy are both effective options, according to Nature Reviews Disease Primers 2

Pharmacotherapy: When and What to Use

  • Three out of five randomized controlled trials demonstrated the superiority of N-acetylcysteine to placebo, as reported in Nature Reviews Disease Primers 3
  • Clomipramine requires at least 8-12 weeks at maximum tolerated dose before declaring treatment failure, as noted in Nature Reviews Disease Primers 3
  • Monitoring for serious adverse effects, such as seizures, cardiac arrhythmias, and serotonergic syndrome, is necessary when using clomipramine, especially when combined with other serotonergic agents, as cautioned in Nature Reviews Disease Primers 3
  • Do not prematurely discontinue clomipramine trials before completing 8-12 weeks at maximum tolerated dose, as advised in Nature Reviews Disease Primers 3

Trichotillomania Treatment Guidelines

Diagnosis and Classification

  • Trichotillomania is classified as an obsessive-compulsive related disorder, not an impulse control disorder, which informs treatment selection 4, 5

Treatment Approach

  • The American Academy of Child and Adolescent Psychiatry and other guidelines recommend a combination of behavioral therapy and medication for optimal treatment outcomes, with habit-reversal training being a key component 4, 5

    Pharmacological Treatment

  • N-acetylcysteine and clomipramine are considered effective pharmacological treatments for trichotillomania, with N-acetylcysteine being the preferred first-line medication due to its significant benefits and low risk of side effects 4, 5

Treatment of Trichotillomania

Patient Adherence and Treatment Success

  • Patient adherence to between-session homework exercises is the most robust predictor of both short-term and long-term treatment success, as reported by the Nature Reviews Disease Primers 6

Treatment Duration and Maintenance

  • Continue successful interventions for at least 12-24 months after achieving remission, given the chronic nature of the condition, as recommended by the Nature Reviews Disease Primers 6

REFERENCES

1

practitioner review: assessment and treatment of body dysmorphic disorder in young people. [LINK]

Journal of Child Psychology and Psychiatry and Allied Disciplines, 2024

2

obsessive-compulsive disorder. [LINK]

Nature Reviews Disease Primers, 2019

3

obsessive-compulsive disorder. [LINK]

Nature Reviews Disease Primers, 2019

4

obsessive-compulsive disorder. [LINK]

Nature Reviews Disease Primers, 2019

5

obsessive-compulsive disorder. [LINK]

Nature Reviews Disease Primers, 2019

6

obsessive-compulsive disorder. [LINK]

Nature Reviews Disease Primers, 2019